Overview

Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study

Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the long-term safety and tolerability of vortioxetine, once daily (QD), in participants with major depressive disorder.
Phase:
Phase 3
Details
Lead Sponsor:
Takeda
Treatments:
Vortioxetine